Answer
Yes, patients should be screened for tuberculosis before starting upadacitinib hemihydrate, and it should not be given to patients with active tuberculosis.
Sources for this answer
- RINVOQ 15 mg prolonged-release tabletsAbbVie Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 28Document updated
Sources checked